Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic
We have developed a Drosophila lung cancer model by targeting Ras1G12V—alone or in combination with PTEN knockdown—to the Drosophila tracheal system. This led to overproliferation of tracheal tissue, formation of tumor-like growths, and animal lethality. Screening a library of FDA-approved drugs ide...
Main Authors: | Benjamin D. Levine, Ross L. Cagan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-02-01
|
Series: | Cell Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124716000358 |
Similar Items
-
Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
by: David Balakirouchenane, et al.
Published: (2020-04-01) -
Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
by: Adil Daud, et al.
Published: (2017-01-01) -
Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models
by: XuSha Zhou, et al.
Published: (2021-09-01) -
Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib
by: Diana Valentina Tudor, et al.
Published: (2021-04-01) -
Ocular toxicity due to Trametinib and Dabrafenib
by: Stephanie Sarny, et al.
Published: (2017-08-01)